34 related articles for article (PubMed ID: 15682847)
1.
Jeltema HR; van Dijken BRJ; Tamási K; Drost G; Heesters MAAM; van der Hoorn A; Glaudemans AWJM; van Dijk JMC
Ann Nucl Med; 2024 May; ():. PubMed ID: 38720053
[TBL] [Abstract][Full Text] [Related]
2. [
Kubota Y; Sato T; Han Q; Hozumi C; Morinaga S; Mizuta K; Tsunoda T; Hoffman RM
In Vivo; 2024; 38(1):253-258. PubMed ID: 38148095
[TBL] [Abstract][Full Text] [Related]
3. Using max standardized uptake value from positron emission tomography to assess tumor responses after lung stereotactic body radiotherapy for different prescriptions.
Ding M; Zollinger W; Ebeling R; Heard D; Posey R
J Appl Clin Med Phys; 2018 Nov; 19(6):226-233. PubMed ID: 30216639
[TBL] [Abstract][Full Text] [Related]
4. Response criteria in solid tumors (PERCIST/RECIST) and SUV
Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
[TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis of pre- and post-treatment PET-CT scans using deformable image registration methods.
Stapleford LJ; Landry JC; Schreibmann E; Waller A; Pan L; Kim S; Chen Z; Crocker I; Fox TH
J Radiosurg SBRT; 2012; 2(1):51-62. PubMed ID: 29296342
[TBL] [Abstract][Full Text] [Related]
6. Positron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response Monitoring.
Challapalli A; Aboagye EO
Front Oncol; 2016; 6():44. PubMed ID: 26973812
[TBL] [Abstract][Full Text] [Related]
7. Illustrative cases of false positive biopsies after stereotactic body radiation therapy for lung cancer based on abnormal FDG-PET-CT imaging.
Singhvi M; Lee P
BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23345491
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of ¹¹C-methionine PET/CT in patients with plasma cell malignancy: comparison with ¹⁸F-FDG PET/CT.
Nakamoto Y; Kurihara K; Nishizawa M; Yamashita K; Nakatani K; Kondo T; Takaori-Kondo A; Togashi K
Eur J Nucl Med Mol Imaging; 2013 May; 40(5):708-15. PubMed ID: 23340595
[TBL] [Abstract][Full Text] [Related]
9. The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study.
Solanki AA; Weichselbaum RR; Appelbaum D; Farrey K; Yenice KM; Chmura SJ; Salama JK
Radiat Oncol; 2012 Dec; 7():216. PubMed ID: 23244066
[TBL] [Abstract][Full Text] [Related]
10. Application of metabolic PET imaging in radiation oncology.
Zhu A; Marcus DM; Shu HK; Shim H
Radiat Res; 2012 Apr; 177(4):436-48. PubMed ID: 22339451
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study.
Wiegman EM; Pruim J; Ubbels JF; Groen HJ; Langendijk JA; Widder J
Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1059-63. PubMed ID: 21210108
[TBL] [Abstract][Full Text] [Related]
12. CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment.
Vahdat S; Oermann EK; Collins SP; Yu X; Abedalthagafi M; Debrito P; Suy S; Yousefi S; Gutierrez CJ; Chang T; Banovac F; Anderson ED; Esposito G; Collins BT
J Hematol Oncol; 2010 Feb; 3():6. PubMed ID: 20132557
[TBL] [Abstract][Full Text] [Related]
13. A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy.
Henderson MA; Hoopes DJ; Fletcher JW; Lin PF; Tann M; Yiannoutsos CT; Williams MD; Fakiris AJ; McGarry RC; Timmerman RD
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):789-95. PubMed ID: 19473777
[TBL] [Abstract][Full Text] [Related]
14. Current status of stereotactic body radiotherapy for lung cancer.
Nagata Y; Matsuo Y; Takayama K; Norihisa Y; Mizowaki T; Mitsumori M; Shibuya K; Yano S; Narita Y; Hiraoka M
Int J Clin Oncol; 2007 Feb; 12(1):3-7. PubMed ID: 17380434
[TBL] [Abstract][Full Text] [Related]
15. Advances in positron emission tomographic imaging of lung cancer.
Chen DL; Dehdashti F
Proc Am Thorac Soc; 2005; 2(6):541-4, 512. PubMed ID: 16352762
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy imaging in patients for oncological applications.
Peñuelas I; Haberkorn U; Yaghoubi S; Gambhir SS
Eur J Nucl Med Mol Imaging; 2005 Dec; 32 Suppl 2():S384-403. PubMed ID: 16180032
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy.
Ishimori T; Saga T; Nagata Y; Nakamoto Y; Higashi T; Mamede M; Mukai T; Negoro Y; Aoki T; Hiraoka M; Konishi J
Ann Nucl Med; 2004 Dec; 18(8):669-74. PubMed ID: 15682847
[TBL] [Abstract][Full Text] [Related]
18. The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET.
Hsieh HJ; Lin SH; Lin KH; Lee CY; Chang CP; Wang SJ
Ann Nucl Med; 2008 Jul; 22(6):533-8. PubMed ID: 18670862
[TBL] [Abstract][Full Text] [Related]
19. [Comparative analysis of the informative value of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography in the differential diagnosis of solitary lung masses].
Tlostanova MS; Avetisian AO; Kozak AR
Vestn Rentgenol Radiol; 2014; (3):13-9. PubMed ID: 25782293
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
